(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2011 (27.01.2011)

PCT

(10) International Publication Number
WO 2011/011584 A1

(51) International Patent Classification:
C07K 14/18 (2006.01) *C12N 15/867* (2006.01)

(21) International Application Number:
PCT/US2010/042870

(22) International Filing Date:
22 July 2010 (22.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/228,491 24 July 2009 (24.07.2009) US

(71) Applicant *(for all designated States except US)*: **IMMUNE DESIGN CORP** [US/US]; 1124 Columbia Street, Suite 700, Seattle, WA 98104 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALLEN, James, M.** [US/US]; 1124 Columbia Street, Suite 700, Seattle, WA 98104 (US). **VAN HOEVEN, Neal, S.** [US/US]; 1124 Columbia Street, Suite 700, Seattle, WA 98104 (US). **LI, Jin Zhong** [CN/US]; 1124 Columbia Street, Suite 700, Seattle, Washington 98104 (US). **SLOAN, Derek, D.** [US/US]; 1124 Columbia Street, Suite 700, Seattle, WA 98104 (US). **DUBENSKY, Thomas W., Jr.** [US/US]; 1124 Columbia Street, Suite 700, Seattle, WA 98104 (US).

(74) Agents: **ROSOK, Mae Joanne** et al.; Seed Intellectual Property Law Group PLLC, 701 Fifth Avenue, Suite 5400, Seattle, Washington 98104-7092 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: LENTIVIRAL VECTORS PSEUDOTYPED WITH A SINDBIS VIRUS ENVELOPE GLYCOPROTEIN




FIGURE 2

(57) **Abstract**: Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).

WO 2011/011584 A1